Your browser doesn't support javascript.
Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV.
Liu, Wang-Da; Pang, Man Wai; Wang, Jann-Tay; Sun, Hsin-Yun; Huang, Yu-Shan; Lin, Kuan-Yin; Wu, Un-In; Li, Guei-Chi; Liu, Wen-Chun; Su, Yi-Ching; He, Pu-Chi; Lin, Chia-Yi; Yeh, Chih-Yu; Cheng, Yu-Chen; Yao, Yi; Chen, Yi-Ting; Wu, Pei-Ying; Chen, Ling-Ya; Luo, Yu-Zhen; Chang, Hsi-Yen; Sheng, Wang-Huei; Hsieh, Szu-Min; Chang, Sui-Yuan; Hung, Chien-Ching; Chang, Shan-Chwen.
  • Liu WD; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Pang MW; Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Wang JT; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Sun HY; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Huang YS; Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
  • Lin KY; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Wu UI; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Li GC; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Liu WC; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Su YC; Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
  • He PC; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Lin CY; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Yeh CY; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Cheng YC; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Yao Y; Department of Medical Education, National Taiwan University, Taipei, Taiwan.
  • Chen YT; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
  • Wu PY; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
  • Chen LY; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Luo YZ; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Chang HY; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan.
  • Sheng WH; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan.
  • Hsieh SM; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan.
  • Chang SY; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan.
  • Hung CC; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan.
  • Chang SC; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
J Virus Erad ; 8(4): 100308, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: covidwho-2181183
ABSTRACT

Background:

A community COVID-19 outbreak caused by the B.1.1.7 SARS-CoV-2 variant occurred in Taiwan in May 2021. High-risk populations such as people living with HIV (PLWH) were recommended to receive two doses of COVID-19 vaccines. While SARS-CoV-2 vaccines have demonstrated promising results in general population, real-world information on the serological responses remains limited among PLWH.

Methods:

PLWH receiving the first dose of SARS-CoV-2 vaccine from 2020 to 2021 were enrolled. Determinations of anti-SARS-CoV-2 spike IgG titers were performed every one to three months, the third dose of the SARS-CoV-2 vaccine or confirmed SARS-CoV-2 infection. All serum samples were tested for anti-nucleocapsid antibody and those tested positive were excluded from analysis.

Results:

A total of 1189 PLWH were enrolled 829 (69.7%) receiving two doses of the AZD1222 vaccine, 232 (19.5%) of the mRNA-1273 vaccine, and 128 (10.8%) of the BNT162b2 vaccine. At all time-points, PLWH receiving two doses of mRNA vaccines had consistently higher antibody levels than those receiving the AZD1222 vaccine (p <0.001 for all time-point comparisons). Factors associated with failure to achieve an anti-spike IgG titer >141 BAU/mL within 12 weeks, included type 2 diabetes mellitus (DM) (adjusted odds ratio [aOR], 2.24; 95% CI, 1.25-4), a CD4 T cell count <200 cells/mm3 upon receipt of the first dose of vaccination (aOR, 3.43; 95% CI, 1.31-9) and two homologous AZD1222 vaccinations (aOR, 16.85; 95%CI, 10.13-28). For those receiving two doses of mRNA vaccines, factors associated with failure to achieve an anti-spike IgG titer >899 BAU/mL within 12 weeks were a CD4 T cell count <200 cells/mm3 on first-dose vaccination (aOR, 3.95; 95% CI, 1.08-14.42) and dual BNT162b2 vaccination (aOR, 4.21; 95% CI, 2.57-6.89).

Conclusions:

Two doses of homologous mRNA vaccination achieved significantly higher serological responses than vaccination with AZD1222 among PLWH. Those with CD4 T cell counts <200 cells/mm3 and DM had consistently lower serological responses.
Palavras-chave

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo experimental / Estudo prognóstico Tópicos: Vacinas / Variantes Idioma: Inglês Revista: J Virus Erad Ano de publicação: 2022 Tipo de documento: Artigo País de afiliação: J.jve.2022.100308

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo experimental / Estudo prognóstico Tópicos: Vacinas / Variantes Idioma: Inglês Revista: J Virus Erad Ano de publicação: 2022 Tipo de documento: Artigo País de afiliação: J.jve.2022.100308